See our

Become part of the switchSENSE® community

Daniel Schwarz, PhD

“At Merck, we see the switchSENSE® technology as a versatile and highly valuable tool to positively impact preclinical drug discovery projects. switchSENSE® has proven to be extremely helpful when it comes to the analysis of interactions between a drug candidate and its target protein. Especially the formation of ternary complexes (DNA-Enzyme-Drug) and being able to detect the inhibition of the enzymatic activity is a big benefit. Moreover, we highly appreciate the support and the competence of the Dynamic Biosensors team.”

Daniel Schwarz, PhD, Principal Scientist Molecular Interactions and Head of Laboratory, Merck KGaA, Darmstadt, Germany

Prof. Deborah Power

switchSENSE® biosensor will certainly increase CCMAR’s scientific capacity, but it should be seen as a far-reaching investment, first because it can also be used by the entire academic and industrial community, and second because it will enable us to identify more rapidly new biomolecules of marine origin with potential for human use.”

Prof. Deborah Power, senior researcher at Centre for Marine Sciences (CCMAR),
full professor at the University of Algarve,
Faro, Portugal

Jean van den Elsen, PhD

switchSENSE® gives researchers new tools to understanding protein-ligand interaction by combining traditional kinetics measurements with changes in molecular size and shape.”

Jean van den Elsen PhD, Reader in Molecular and Structural Biology
University of Bath – Bath, UK

Felix Hartlepp, PhD

“Our lab used the ultra-high sensitivity switchSENSE® Technology from Dynamic Biosensors to confirm the pM affinities of our Nano-Traps. switchSENSE® also confirmed structural data through its rapid absolute sizing model.”

Felix Hartlepp, PhD, VP Research & Technology,
ChromoTek GmbH – Planegg-Martinsried, Germany

Till Bachmann, PhD

“A remarkable technology for a fresh new angle on molecular interaction.”

Till Bachmann, PhD, Deputy Head of Division of Infection and Pathway Medicine
Medicine and Veterinary Medicine, University of Edinburgh – Edinburgh, Scotland

Dirk Ullmann, PhD

switchSENSE® is one of the few new technologies which provide a clear value-added. In the case of switchSENSE, this is the additional information on size and conformational changes of the binding partners. Especially the observation of conformational changes upon binding can be of great value to researchers in small molecule research.”

Dirk Ullmann, PhD, Executive Vice President Lead Discovery
Evotec AG – Hamburg, Germany

Joachim Nickel, PhD

„We have tested switchSENSE® with a well-characterized ligand-receptor interaction. I was amazed how switchSENSE allows to track each single measurement step in detail and about the wealth of information this technology provides. Binding parameters as well as sizing data confirmed our previous results from many previously conducted experiments – all in one single measurement.”

Joachim Nickel, PhD, Group Leader
University Clinic of Wuerzburg / Fraunhofer Institute for Interfacial Engineering and Biotechnology – Wuerzburg, Germany

Tim Carlton

switchSENSE® was a revelation: it solved a seemingly intractable antibody/antigen measurement with ease. The key was its remarkably versatile architecture, switchSENSE® seems only limited by the imagination of the researcher.”

Tim Carlton, Senior Scientist
VHsquared Ltd. – Cambridge, UK

Günter Müller, PhD

„We have used switchSENSE® to characterize the binding of insuline to a certain receptor. I am amazed by the wealth of information we could extract from these measurements. Apart from mere binding studies, the function of the signaling pathway could be traced in detail with switchSENSE®. This would not have been possible with any conventional sensor system.“

Günter Müller, PhD, Group Leader
Helmholtz Zentrum, German Research Center for Environmental Health – Munich, Germany

Michael Schraeml, PhD

switchSENSE® allows us to measure affinity and kinetics of DNA-binding proteins which we are unable to analyze with any other method. Even more, switchSENSE® enables us to go one step further and characterize the enzymatic function of those proteins due to its unique dynamic measurement mode.”

Michael Schraeml, PhD, Head of Protein and Enzyme Technologies
Roche Diagnostics GmbH – Penzberg, Germany

Bruce Carrington, PhD

„Conformational change provides a more biologically relevant description of molecular interactions than just kinetics alone. Using switchSENSE® will enable us to accelerate our pursuit of breakthrough molecules.”

Bruce Carrington, PhD, Senior Principal Scientist
UCB Pharma – Slough, UK

Jurgen Haustraete, PhD

“The architectures available from switchSENSE® are uniquely placed to offer us the flexibility and extraordinary sensitivity in our molecular interaction studies. This new technology will immediately open up a number of new research approaches, previously unattainable from existing technologies.”

Jurgen Haustraete, PhD, Head of Protein Service Facility
VIB Inflammation Research Center – Ghent, Belgium

Prof. Richard M Napier

switchSENSE® gives imaginative researchers a fresh new set of options for studying molecular interactions.”

Prof. Richard M Napier, School of Life Sciences
University of Warwick – Coventry, UK

Prof. Joerg Kleiber

“We have been using Dynamic Biosensors’ DRX 2400 instrument for biomarker analysis and research for quite a while now. What strikes me is the enormous flexibility and versatility the system provides. I do not know of any other system which allows the analysis of protein and DNA biomarkers on the same chip in the same measurement.”

Prof. Joerg Kleiber, Molecular Biotechnology Department
University of Applied Sciences Weihenstephan-Triesdorf – Weihenstephan, Germany


What are you interested in? *

Consumables & Reagents
Technical Support
Quotes & Orders

Instruments & Applications
Technical & Software Support
Assay Development

New to switchSENSE®
General Info & Evaluation

Dynamic Biosensors Data Privacy Policy

Contact Specialist